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Stroke remains a leading cause of death and disability in the world. Over the past few decades our under-
standing of the pathophysiology of stroke has increased, but greater insight is required to advance the field
of stroke recovery. Clinical treatments have improved in the acute time window, but long-term therapeutics
remain limited. Complex neural circuits damaged by ischemia make restoration of function after stroke diffi-
cult. New therapeutic approaches, including cell transplantation or stimulation, focus on reestablishing these
circuits through multiple mechanisms to improve circuit plasticity and remodeling. Other research targets
intact networks to compensate for damaged regions. This review highlights several important mechanisms
of stroke injury and describes emerging therapies aimed at improving clinical outcomes.Pathophysiology of Stroke
The lack of blood flow during a stroke results in an intricate path-
ophysiological response resulting in neural injury, as depicted in
Figure 1 (Hossmann, 2006). Multiple mechanisms, including ex-
citotoxicity, mitochondrial response, free radical release, protein
misfolding, and inflammatory changes, lead to neural cell loss,
but many of these pathways ultimately pave the way for recov-
ery. Injury and death of astrocytes, as well as white matter injury,
also contribute to cerebral damage. The delicate balance be-
tween detrimental or beneficial effect often relies on the timing
and the magnitude of the factors involved. The inflammatory
response is a prime example of a system that both propagates
ischemic injury and helps promote recovery. Inflammation
initially contributes to cellular injury through the release of cyto-
kines and harmful radicals but eventually helps to remove
damaged tissue, enabling synaptic remodeling. Glial cells also
serve dual roles, helping to regulate the blood-brain barrier,
promoting angiogenesis and synaptogenesis, but conversely
forming the glial scar that may prevent further plasticity (Gleich-
man and Carmichael, 2014). The goal for this review is to provide
a brief overview of the pathophysiology of stroke followed by a
discussion of the current state of stroke recovery research
with an emphasis on those approaches that target multiple
mechanistic pathways. Many of these therapies are aimed at up-
regulating pathways that enhance recovery while reducing the
deleterious pathways triggered by the initial ischemic insult.
Further understanding and optimizing this delicate balance
may facilitate development of effective stroke therapeutics.
Excitotoxicity
CNS ischemia results in a deficiency of glucose and oxygen
leading to the inability of neuronal cells to maintain normal ionic
gradients. Depolarization of these neurons leads to excessive
glutamate release resulting in the intracellular influx of calcium,triggering cell death pathways such as apoptosis, autophagocy-
tosis, and necrotic pathways (Lipton, 1999). This process has
been termed excitotoxicity and is mediated largely through the
glutamatergic pathways involving N-methyl-D-aspartate recep-
tors (NMDARs), a-amino-3-hydroxy-5-methyl-4-isoxazole-pro-
pionic acid receptors (AMPARs), and kainate receptors (Dirnagl
et al., 1999; Moskowitz et al., 2010). The role of calcium in exci-
toxicity also remains complex and has numerous effects in the
ischemic environment. The intracellular increase in calcium trig-
gers mitochondrial dysfunction and activation of free radicals,
phospholipases, and proteases, which lead to cell death or injury
(Szydlowska and Tymianski, 2010). Interestingly, the interplay
between the cells is also critical to the spread of injury after
ischemic insults. Blockage of the gap junctions between cells
in the adult brain reduces neuronal death (Wang et al., 2010),
potentially indicating the important interactions that occur be-
tween cells during neuronal damage. These processes also pro-
mote cerebral edema, which has clinical import in the first few
days after a stroke. Numerous therapeutic approaches have
centered on interrupting pathways triggered by excitotoxicity
to improve stroke recovery, and while often successful in animal
models (Yenari et al., 2001; Namura et al., 2013), translation of
these findings into the clinic remains challenging.
Mitochondrial Alterations
The mitochondria play a critical role in cell energy homeostasis
and are thus prominently involved during ischemia when the en-
ergy balance is disrupted and ATP synthesis is altered. The rapid
influx of calcium experienced with excitoxicity leads to excess
accumulation in the mitochondria, causing dysfunction, which
leads to mitochondrial permeability transition pore (mtPTP)
opening and cytochrome c release (Liu et al., 1996; Murphy
et al., 1999). These events create mitochondrial swelling and
membrane collapse, initiating cell death cascades such asNeuron 87, July 15, 2015 ª2015 Elsevier Inc. 297
Figure 1. Pathophysiology of Stroke
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Reviewapoptosis (Liu et al., 1996). The reactive oxygen species (ROS)
created by the mitochondria also play a prominent role in reper-
fusion injury and cell death in the ischemic environment (Kaloge-
ris et al., 2014). Maintaining mitochondrial integrity and limiting
their induction of apoptotic and oxidative stress pathways in
the cell are important avenues to preventing widespread cell
toxicity from an ischemic insult.
Free Radicals
Brain ischemia also triggers free radicals, which contribute to the
oxidative stresses on neural tissue. The influx of calcium triggers
nitric oxide (NO) production by nitric oxide synthase (NOS) that
leads to injury through the formation of oxygen free radicals
and the production of peroxynitrite (ONOO) (Iadecola, 1997).
The mitochondria undergo dysfunction during ischemia, leading
to further oxidative stress (Kalogeris et al., 2014). NADPH oxi-
dase also plays a critical role in ROS production in the setting
of excitotoxicty and ischemia (Moskowitz et al., 2010). Further-
more, chimeric bone marrow studies have shown that inflamma-
tion contributes with neutrophils releasing inducible NOS (iNOS),
which leads to toxic levels of NO (Garcia-Bonilla et al., 2014;
Moro et al., 2004). Free radicals trigger the PI3-kinase/Akt
pathway as well as upregulate the transcription factor NF-kB.
Interestingly, the timing and environment of activation of this
pathway likely determine whether stroke recovery is improved
or impeded by this signaling cascade (Crack and Taylor, 2005).
Other pathways of interest are the transient receptor potential
(TRP) channels. TRP channels, TRPM7 specifically, are linked298 Neuron 87, July 15, 2015 ª2015 Elsevier Inc.to free radicals in ischemia and likely contribute to increasing
the influx of calcium and cellular toxicity experienced during
decreased oxygenation (Sun et al., 2009). Not only do free radi-
cals contribute to initial toxicity, they also prevent recovery,
which makes them an important post-stroke therapeutic target
(Miyamoto et al., 2013). Numerous methods have reduced the
oxidative stress from free radicals in ischemic injury and shown
neurologic improvement in preclinical models. Combining the
regulation of these pathways with other ischemic injury mecha-
nisms may lead to novel therapeutics.
Protein Misfolding
The largest stores of intracellular calcium reside in the endo-
plasmic reticulum (ER), an organelle that regulates protein syn-
thesis and responds to protein misfolding (Zhang et al., 2014).
These processes are largely affected by ER stress induced by
ischemic injury (Roussel et al., 2013). As excitotoxic changes
occur in neural cells, the sarcoplasmic/ER calcium ATPase
(SERCA) pump fails due to energy depletion and adds to the
occurrence of cell death (Szydlowska and Tymianski, 2010).
The increased accumulation of misfolded proteins also trigger
the protein kinase-like ER kinase (PERK) pathway regulating
eIF2a kinase activation, which halts new protein synthesis
(Althausen et al., 2001). The phosphorylation of eIF2a has been
explored as a means to alter damage in cerebral ischemia.
Inositol requiring enzyme 1 (IRE1) is another protein involved in
the misfolding of proteins that has been shown to induce
apoptotic pathways during periods of ER stress (Morimoto
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150 kDa and binding immunoglobulin protein), which normally
guide protein synthesis, are also altered in ischemia, and upre-
gulation of these chaperones may reduce apoptosis and limit
damage from ischemia (Roussel et al., 2013). The cumulative ef-
fect of SERCA pump failure and chaperone misfunctioning make
ER stress and its role in protein misfolding important targets for
acute stroke therapies.
Astrocytic Changes and White Matter Injury
The glial cells (astrocytes and oligodendrocytes) surrounding
neurons and their connections play an integral role in the brain’s
response to ischemia and recovery. Axons and glial cells are inti-
mately interwoven, forming the connections and signals that
compose neural activity and are poised as key therapeutic tar-
gets to enhance recovery mechanisms and reduce injurious
ones. At baseline, white matter receives less blood supply than
gray matter, and this may predispose white matter to ischemic
damage with milder variations in blood flow. During ischemic
injury, glial cells are damaged by similar injury pathways to neu-
rons including glutamate toxicity (Sa´nchez-Go´mez et al., 2011).
Ischemia also triggers P2X7 receptors on oligodendrocytes,
which contribute to calcium overload andmitochondrial depolar-
ization (Wang et al., 2009). One of the key differences between
the effects of ischemia on white matter compared with gray mat-
ter is the reliance on oligodendrocytes for functional deficits as
well as the reduced influence of NMDA-type glutamate receptors
on white matter injury (Matute et al., 2013).
After the acute response to hypoxic conditions, the glia also
help to modulate inflammation and recovery. Although the glial
scar has been shown to prevent new growth, it also exhibits
positive effects of helping to restore the integrity of the blood-
brain barrier. Additionally, reactive astrocytes, associated with
formation of the glial scar, also modulate trophic factors, which
enhance recovery (Rolls et al., 2009). Thus, glia play a prominent
role in modulating the injury cascade and eventual recovery after
stroke.
Inflammatory Response and the Role of the Blood-Brain
Barrier
The immune system plays a vital role in the CNS’s response
to ischemia and to eventual recovery of function. An intricate
cascade of immune cells and inflammatory factors cause
blood-brain barrier breakdown, remodeling of the post-stroke
tissue, and also offer a margin of neuroprotection from the harsh
excitotoxic post-stroke environment of increased free radicals
and enzymes (Iadecola and Anrather, 2011). Initially, microglia
respond to the ischemic insult followed by an increase of den-
dritic cells, macrophages, and lymphocytes, and as astroglia
are reduced and blood-brain barrier breakdown occurs, an influx
of neutrophilic cells permeates the infarct and peri-infarct region
(Gelderblom et al., 2009). Proinflammatory cytokines (i.e., tumor
necrosis factor-a and interleukin-1b) are also released as well as
free radicals by the immune cells in the post-stroke tissue, which
increase the inflammatory response and upregulate cell adhe-
sion molecule expression, further propagating the immune
response (Huang et al., 2006). Immune cells also release induc-
ible NO synthetase, which contributes to the detrimental effect of
NO in brain ischemia, as noted above (Moro et al., 2004). Addi-
tionally, matrix metalloproteins (MMPs) and myeloperoxidase(MPO) production are elevated by the immune response, both
of which are major factors leading to blood-brain barrier break-
down (Bao Dang et al., 2013). Inhibiting the acute inflammatory
response after stroke has been shown to decrease injury and
improve neurologic outcome in rodent stroke models (Arac
et al., 2011), but has not yet been translated into the clinic.
Components of the complement cascade play a role in
ischemic injury and recovery. The amount of complement pro-
teins increases after ischemia (Pedersen et al., 2004). Evidence
suggests that complement proteins tag synapses for removal
by microglia to enable synaptic pruning and remodeling (Ste-
phan et al., 2012). Another role of complement proteins (C3a
and C5a, in particular) is protecting neurons from the NMDA
excitotoxicity that occurs post-stroke (van Beek et al., 2001;
Mukherjee et al., 2008). Immune cells such as eosinophils also
produce trophic factors such as nerve growth factor (NGF) and
neurotrophin-3 that promote neuronal outgrowth and may have
a significant impact on post-infarct plasticity (Foster et al.,
2011). Microglia also play a prominent role producing glial cell-
derived neurotrophic factor (GDNF) and brain-derived neurotro-
phic factor (BDNF), which promote neural growth and healing
(Wang et al., 2013; Yang et al., 2012). Insulin-like growth factor
(IGF-1), another molecule modulated by microglia, enhances
axonal growth as well as neurogenesis in the subventricular
zone (SVZ) to improve stroke recovery (Butovsky et al., 2006; La-
lancette-He´bert et al., 2007). Cytokines, such as transforming
growth factor-b and interleukin-10, often serve dual roles of
driving the inflammatory response but also promoting tissue
repair and resolution of inflammation depending on timing and
the environment (Iadecola and Anrather, 2011).
The multifaceted immune response has both a beneficial and
deleterious effect on the surviving tissue. The timing and levels of
inflammatory factors and cells contribute to the balance of post-
stroke injury and the restorative process (Peruzzotti-Jametti
et al., 2014). The immune response has a positive role on recov-
ery by pruning unwanted synapses and allowing for the forma-
tion of new growth and connections. However, there is also a
negative effect of the inflammatory response with rodent models
showing decreased stroke volume and infarct size in immuno-
deficient animals (Hurn et al., 2007). While neutrophils release
cytokines and radicals that worsen the inflammatory response,
inflammatory cells also help remove debris and damaged tissue
to facilitate recovery. The balance of the inflammatory response
after stroke is critical for recovery, and investigation into the
components that lead to improved recovery and plasticity versus
those that worsen ischemic damage is an exciting area for
further research and translational investigations.
Stroke Therapies
The complex injury pathways described above often disrupt the
cortical maps that form the neural representation of our body.
Increased spine formation and axonal sprouting weeks after
ischemia demonstrate enhanced neural plasticity in the peri-
infarct area and contralesional hemisphere as brain regions
reorganize, likely to restore function (Brown et al., 2007). Alter-
ations in synaptic function and vasculature have been shown
to correlate with behavioral improvement after stroke as the
brain remaps to compensate for damaged networks (WinshipNeuron 87, July 15, 2015 ª2015 Elsevier Inc. 299
Table 1. Current Approaches for Stroke Therapeutics
Restoration of Blood Flow (Acute)
Intra-arterial and intravenous tPA
Mechanical thrombectomy
Magnetic resonance-guided focused ultrasound
Neuroprotection (Acute)
Hypothermia
PSD-95
Cell Replacement Therapies (Recovery)
Endogenous stem cells
Exogenous stem cells
Induced stem cells
Modulation of Circuits (Recovery)
Transcranial direct current stimulation
Transcranial magnetic stimulation
Optogenetic stimulation
MR-guided focus ultrasound
Stereotactic radiotherapy
Brain-Machine Interface (Recovery)
Cortical signals to induce movement
Spinal cord signals to induce movement
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processes that occur after the initial ischemic damage, a single
mechanistic pathway will likely not be sufficient to greatly
improve functional outcomes. Strategies such as cell therapies,
stimulation, or mild hypothermia that affect several of these
pathways, or a combination of therapeutic approaches, may
prove to be the most promising for clinical translation.
Currently, the mainstay of acute stroke therapy is intravenous
administration of tissue plasminogen activator (tPA), which has
been FDA approved within a narrow time window. Endovascular
therapies utilizing intra-arterial mechanical or chemical throm-
bolysis also improve outcomes. After the acute time period,
focused physical rehabilitation of the injured area is the primary
current therapy that is proven to be effective (Veerbeek et al.,
2014). Re-organization of the cortex has been observed with
rehabilitation in pre-clinical models as well as in humans (Liepert
et al., 2001). While rehabilitation can be effective, and encour-
aging results have been demonstrated with constraint induced
movement therapy and other techniques (Hoare et al., 2007),
the extent of neurologic recovery is still limited and novel ap-
proaches to augment or enhance the body’s endogenous regen-
erative abilities are required (Table 1).
Restoring Circulation
Clinical treatments in use currently focus on restoration of blood
flow to the penumbral tissue. Dendrites and their spine
morphology are adversely affected by ischemia; however, re-
covery is possible even with severe ischemia if blood flow is
restored quickly (Zhang et al., 2005). After many decades of
pessimism surrounding stroke therapies, tPA given intrave-
nously showed efficacy in a major clinical trial if given within
3 hr of symptom onset (National Institute of Neurological Disor-
ders and Stroke rt-PA Stroke Study Group, 1995). More recently,300 Neuron 87, July 15, 2015 ª2015 Elsevier Inc.intravenous tPAwas shown to be advantageous up to 4.5 hr after
stroke in a large European trial (Hacke et al., 2008). Endovascular
interventions of mechanical and chemical clot removal are often
used clinically and have shown great promise with recent clinical
trials demonstrating benefit within the acute timeframe (Ber-
khemer et al., 2015). The use of noninvasive transcranial Doppler
ultrasound-assisted thrombolysis (in combination with intrave-
nous tPA) is also being tested in early phase clinical trials
(Barreto et al., 2013). Given the variety of strokes and patient dif-
ferences in collaterals and vasculature, selecting the correct pa-
tients may be critical for the ultimate success of these therapies
(Liebeskind et al., 2014). Unfortunately, a vast majority of stroke
patients are not able to receive the acute treatments because of
the narrow time windows. Further investigations studying the in-
flammatory and oxidative stresses as blood flow is restored will
also help elucidate how the brain heals from ischemic injury.
Therapies targeting later time windows are also needed to help
recover from tissue that has been damaged before blood flow
can be restored.
Disruption of Injury Pathways and Neuroprotection
The peri-infarct region appears to contain the highest potential
for plasticity after stroke, with factors promoting growth and
axonal sprouting expressed in this territory (Carmichael et al.,
2005). Minimizing the damage to these areas and maximizing
the potential for restoration are the goals of many of the neuro-
protective strategies. Mechanisms that degrade and remodel
the extracellular matrix (ECM), such as matrix metalloprotei-
nases, are also upregulated in this region (Zhao et al., 2006).
Additionally, angiogenesis and neurotrophic factors such as
BDNF, which likely promote plasticity after stroke, are modu-
lated in the area surrounding the infarct (Clarkson et al., 2011).
Despite their success in animal models, clinical trials for multiple
neuroprotective strategies have proven uninspiring. Multiple ex-
planations exist for this (Dirnagl et al., 1999). One reason is the
inadequacy of current animal models. The human brain and
response to injury is far more complex than in the rodent. The
variability in human anatomy is also difficult to represent in
mouse models genetically engineered to be identical. Addition-
ally, young rodents are most commonly used in the laboratory
setting due to expenses, although differences in response to
stroke are seen between young and older animals. Another dif-
ference is that outcome measures can be much more precisely
designed and evaluated in the preclinical setting compared
with clinical scales that may not truly assess the subtleties of
stroke phenotypes. Timing of these therapies is another critical
component and is much more controlled in the lab environment
compared with clinical application, where administration of a
drug can be delayed for hours or days depending on the pa-
tient’s presentation. A recent trial studying the effect of magne-
sium given acutely after stroke developed a pathway for rapid
delivery of medications. In this trial, magnesium was given in
ambulances before the patients arrived at the hospital (Saver
et al., 2014). Although this trial was negative, the methodology
will serve as a guide for future trials whose treatment effect is
contingent on rapid drug administration.
While affecting a single pathway in an animal model is suffi-
cient to prevent injury, multiple pathwaysmay need to be disrup-
ted in humans to yield similar results. Mild brain hypothermia
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tection in rodent stroke models (Zhao et al., 2007), improves
neurologic outcomes for patients with a particular type of stroke
(global cerebral ischemia) secondary to cardiac arrest and
neonatal hypoxic-ischemic encephalopathy (Shankaran et al.,
2012; Bernard et al., 2002). Therapeutic hypothermia after
cardiac arrest has now become a recommended guideline for
clinical care (Peberdy et al., 2010). Mild hypothermia is currently
being investigated as an acute stroke therapy, with trials to date
proving the feasibility of this approach (Piironen et al., 2014).
Another promising acute neuroprotective strategy targets the
post-synaptic density-95 protein (PSD-95). PSD-95 connects
NMDA receptors to signaling pathways necessary for the excito-
toxic cascade and inhibiting these circuits reduces stroke
volume in primates (Cook et al., 2012). A recently published pro-
spective, randomized, double-blind controlled trial demon-
strated safety and improved neurologic outcome and fewer
acute infarcts in patients undergoing endovascular intracranial
aneurysm repair who received a PSD-95 inhibitor (Hill et al.,
2012). As barriers to accurately mimic clinical practice in the
laboratory are reduced and the ability to manipulate multiple
recovery pathways are improved, more effective neuroprotec-
tive therapies can be developed.
Cell-Based Therapies
Stem cell therapy is an exciting area of research that has entered
the clinical arena with multiple ongoing trials. Stem cells are
pluripotent or multipotent cells that have the ability to trans-
form into multiple cell types and are self-perpetuating. Endoge-
nous therapeutic strategies focus on increasing mobilization,
longevity, and production of neural stem cells in the SVZ and
dentate gyrus. Exogenous stem cell treatments refer to trans-
planted cells from another source into a patient. Exogenous
stem cells have been delivered to the brain via the blood stream
or direct transplantation and have shown great promise in animal
models to enhance stroke recovery.
Endogenous Stem Cells. Neural progenitor cells (NPCs), which
inhealthmigratealong the rostralmigratorysystemto theolfactory
lobe and other brain regions, traverse to injured areas of the brain
in the setting of neurological insult (Goings et al., 2004). Brain
ischemia results in upregulation of endogenous NPCs and some-
times differentiation into the predominant cell type of the injured
region (Arvidsson et al., 2002; Parent et al., 2002). Therapeutic ap-
proaches have focused on augmenting the brain’s normal endog-
enous reaction to injury. Multiple pathways induce neurogenesis,
including those triggered by numerous neurotrophic and growth
factors suchasGDNF,BDNF,granulocyte colony-stimulating fac-
tor (G-CSF), and insulin growth factor (IGF-1) (Kobayashi et al.,
2006;Dempseyetal., 2003).Alternativemechanismsof increasing
endogenous NPC proliferation include anti-inflammatory drugs
like indomethacin, non-codingRNA, and hormones suchaseryth-
ropoietin (Hoehn et al., 2005; Schouten et al., 2012; Wang et al.,
2004). Delivering G-CSF and IGF-1 to alter key survival pathways
such as the phosphoinositide 3-kinase-Akt pathway are able to
reduce NPC death (Lee et al., 2006). Current clinical trials are
investigating the ability of G-CSF to mobilize endogenous bone
marrow cells as well as utilizing its neuroprotective effects to
determine efficacy in stroke recovery (Dunac et al., 2007; Kawada
et al., 2006).Increasing the numbers of migrating endogenous stem cells
can be achieved using various chemokine receptors such as
stromal derived factor1 and integrin b1 (Ohab et al., 2006; Yan
et al., 2007), and manipulation of ECM components or electrical
fields to guide endogenous NPCs has been investigated (Lee
et al., 2006; Babona-Pilipos et al., 2011). However, currently
this research has been limited to the preclinical arena.
Exogenous Stem Cells. Exogenous stem cells are typically
divided into three categories: (1) immortalized cell lines, (2)
NPCs or neural stem cells, and (3) bone marrow-derived he-
matopoietic/endothelial progenitors and stromal cells (Bliss
et al., 2010). Immortalized cell lines have been developed from
tumor cells or from manipulation with oncogenes (such as myc
in the human fetal neural cell line ReN001 of ReNeuron). The
NT2N cells, derived from teratocarcinoma, differentiate into
post-mitotic neuron-like cells with the addition of retinoic acid
and mitotic inhibitors (Andrews et al., 1984; Pleasure and Lee,
1993) and have been shown to improve outcome in several
ischemic models (Saporta et al., 1999). ReNeuron’s cells have
shown dose-dependent recovery in stroke rodent models
(Stroemer et al., 2009) and creatively have been engineered to
be immortalized only in the presence of tamoxifen to reduce
the risk of tumor formation (Stroemer et al., 2008).
Human NPCs are derived from embryonic and fetal tissue and
have the ability to produce astrocytes, neurons, and oligoden-
drocytes (Gage, 2000). In stroke models, NPCs are able to
migrate to the injured regions and improve recovery (Zhang
et al., 2001; Reubinoff et al., 2001; Kelly et al., 2004). NPCs
sometimes integrate into the host tissue and differentiate and
can demonstrate neuronal characteristics, including expression
of synaptic proteins, synapse formation, and electrophysiolog-
ical properties (Bu¨hnemann et al., 2006; Daadi et al., 2009a,
2009b).
Progenitor cells derived from bone marrow, umbilical cord
blood and adipose tissue have all been shown to improve recov-
ery in stroke models (Shen et al., 2007). Many of these sources
are already used for the treatment of other disorders clinically
such as malignancy and can be obtained from autologous har-
vesting. Although numerous cell types are included in each of
these sources and it appears that the mononuclear or marrow
stromal cell component mediates recovery, it is not clear which
subtype is responsible for improving functional outcomes. Multi-
ple trials have been performed or are ongoing using these exog-
enous stem cells (Table 2).
Induced StemCells. The discovery of induced pluripotent stem
(iPS) cells created a paradigm shift in cell therapy. The ability to
transform host somatic cells such as fibroblasts into pluripotent
stem cells bypassed many of the concerns of traditional stem
cell therapy, such as ethical discussions, supply limitations,
and the possible requirement of immunosuppression (Meissner
et al., 2007; Takahashi and Yamanaka, 2006; Wernig et al.,
2007). Further development has led to vector- and transgene-
free techniques to derive iPS cells that improve functional
outcome after brain ischemia (Mohamad et al., 2013). Recently,
it has been possible to generate neural cells directly frommouse
or human fibroblasts using transcription factors, without passing
through a pluripotent phase, which may ultimately have clinical
relevance (Pang et al., 2011).Neuron 87, July 15, 2015 ª2015 Elsevier Inc. 301
Table 2. List of 35 Completed or Ongoing Trials Using Exogenous Stem or Progenitor Cells
Clinical Trial
Identifier Study Type Cell Type
Planned
Enrollment Timing of Delivery
Delivery
Route Status/Results
NCT00473057 Ph1-NR-OL BMMNC 15 3–90 days IA or i.v. Complete, no reported results
NCT02065778 Ph1-NR-OL BMMNC 30 chronic IT Complete, no reported results
NCT01501773 Ph2-R-OL BMMNC 11 7–30 days i.v. Safe, feasible
NCT01849887 Ph1/2-R-DB BMMNC 40 1–3 days i.v. Not currently recruiting
NCT00859014 Ph1-NR-OL BMMNC 10 1–3 days i.v. Safe, feasible
NCT02425670 Ph2-R-SB BMMNC 120 7–30 days i.v. Safe, feasible, no efficacy benefit
NCT01832428 Ph1/2-NR-OL BMMNC 50 chronic IT Recruiting
NCT02245698 Ph1-NR-OL BMMNC 200 subacute/chronic IT Recruiting
NCT02290483 Ph2-R-OL BMMNC 76 1–7 days IA Recruiting
India, 2011 Ph1/2-NR-OL BMMNC 11 3–12 months i.v. Safe, feasible, improved neurologic
outcomes
NCT01436487 Ph2-R-DB multistem 126 1–2 days i.v. Safe, feasible, no efficacy benefit
NCT02117635 Ph2-NR-OL CTX0E03,
NSC
41 2–3 months IC Safe, improved neurologic outcomes
NCT01151124 Ph1-NR-OL CTX0E03,
NSC
12 6–60 months IC Not currently recruiting
NCT01453829 Ph1/2- NR-OL ASC 10 subacute IA Not currently recruiting
NCT01091701 Ph1/2-R-DB MSC 78 <10 days i.v. Not currently recruiting
South Korea,
2010
Ph1/2-R-OL-SB MSC 85 5–7 weeks i.v. Safe, feasible, improved neurologic
outcomes
NCT00875654 Ph2-R-OL MSC 30 <6 weeks i.v. Not currently recruiting
NCT01297413 Ph1/2-NR-OL MSC 35 >6 months i.v. Recruiting
NCT01678534 Ph1/2-R-DB MSC 40 <14 days i.v. Not currently recruiting
Japan, 2011 Ph1-NR-OL 12 1–4 months Safe, feasible, decreased infarct
volume
NCT01714176 Ph1-NR-OL MSC 30 3–60 months IC Recruiting
NCT01716481 Ph3-R-OL MSC 60 <90 days i.v. recruiting
NCT0146172 Ph2-NR-OL MSC 50 1 week to
2 months
i.v. Not currently recruiting
NCT01922908 Ph1/2-R-DB MSC 48 3–10 days i.v. Not currently recruiting
NCT01468064 Ph1/2-R-DB MSC, EPC 90 5 weeks i.v. Recruiting
NCT00761982 Ph1/2-NR-SB CD34+ 20 5–9 days IA Safe, feasible, increased b-NGF
NCT00950521 Ph2-R-OL CD34+ 30 6–60 months IC Complete, no reported results
NCT00535197 Ph1/2-NR-OL CD34+ 5 7 days IA Safe, feasible, reduced infarct volume
NCT01518231 Ph1-R-OL CD34+ 40 <12 months IA Recruiting
NCT01438593 Ph1-NR-OL CD34+ 6 6–60 months IC Not currently recruiting
NCT01310114 Ph2-R-DB PDC 44 acute i.v. Stopped by sponsor
NCT01327768 Ph1-R-SB OEC 6 6–60 months IC Recruiting
NCT01287936 Ph1/2-NR-OL SB623 18 6–36 months IC Safe, improved neurologic outcomes
BB-IND 7082 Ph2-R-OL-SB NT2 18 1–5 years IC Safe, feasible, improved neurologic
outcomes in secondary endpoints
BB-IND 7082 Ph1-NR-OL NT2 12 6–72 months IC Safe, improved neurologic outcomes
ASC, adipose-derived stromal cells; EPC, endothelial progenitor cells; NSC, neural stem cells; OEC, olfactory ensheathing cells; PDC, placenta-
derived stem cells; SB623, human mesenchymal stromal cells; NT2, tetracarcinoma cell-derived neurons; P1, Phase 1 trial; P2, Phase 2 trial;
OL, open label; R, randomized; NR, nonrandomized; DB, double blind; SB, single blind; i.v., intravenous; IA, intra-arterial; IC, intracranial.
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stem cell therapeutics remains elusive. Until mechanisms are
better understood, more intelligent design of trials and applica-
tions will be limited. The ability to fabricate and secrete trophic302 Neuron 87, July 15, 2015 ª2015 Elsevier Inc.factors is common to all stem cell types and may create the
optimum environment for stroke recovery (Bliss et al., 2010).
Enhanced recovery most strongly was associated with a reduc-
tion in apoptosis in a recent meta-analysis evaluating preclinical
Figure 2. Temporal Profile of Changes Induced by Neural Stem Cell
Enhanced Stroke Recovery
This figure was courtesy of Horie et al., 2011. Neurological behavior indicates
motor recovery. The asterisk indicates that Avastin affected all parameters
except for the ones marked; two asterisks indicate the inconclusive effects of
Avastin. BBB, blood-brain barrier; bDG, b-dystroglycan; BVD, blood vessel
density; Iba-1, ionized calcium binding adaptor molecule 1; Tie-2, a receptor
tyrosine kinase; VEGF, vascular endothelial growth factor.
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or systemic immunoregulators alsomay contribute to their ability
to improve stroke recovery by decreasing inflammatory effects
(Horie et al., 2011). NPCs and bone marrow-derived stem cells
augment post-stroke plasticity through upregulation of synapse
formation, dendritic branching, and axonal connections (Liu
et al., 2008; Andres et al., 2011). Stem cells also enhance
angiogenesis and blood-brain barrier repair, which have also
shown to improve recovery (Chen et al., 2003; Horie et al.,
2011). Although small numbers of transplanted cells may inte-
grate into tissue, the extent of behavioral improvement does
not appear to correlate with the number of cells. Additionally,
the timing of synapse formation does not always correlate with
functional improvement (Song et al., 2002; Englund et al.,
2002). Given the complex pathophysiology of stroke, the impor-
tance of timing on the effects of factors, and the balance of sig-
nals in the pathways of recovery as described above (Figure 2), it
is essential to better understand the mechanisms of improve-
ment following stem cell therapy in order to translate these dis-
coveries to clinical applications.
Delivery. While intravenous and intra-arterial techniques likely
rely on inflammatory modulation or paracrine effects of the
cells on the post-ischemic brain, invasive transplantation of
stem cells provides a more direct route for cell-to-cell interac-
tions as well as for the stem cells’ trophic effects. More
advanced delivery methods are also being developed, including
bioengineered polymers to enhance stem cell survival and
efficacy. Inert polymer matrices, such as hydrogels and
particles, were first described for stem cell delivery (Teng
et al., 2002; Zhong et al., 2010). The next step will be developing
interactive polymers that are capable of communicating with
stem cells in their transplanted environment to enhance
recovery.
Clinical Trials. Apart from efficacy, safety is an important
consideration to move forward with cell transplant therapy.
Careful classification and understanding of the biology will becritical for reducing any predilection for tumor formation and
adverse effects (Jandial and Snyder, 2009). The immortalized
cell lines (NT2N) were the first human cells to be used in a clin-
ical Phase I stroke trial and were implanted into the infarcted re-
gion of 12 patients, 6 months to 6 years after a basal ganglia
stroke (Kondziolka et al., 2000). No significant adverse events
occurred and functional improvement was seen in this small
group of patients (p = 0.046). A subsequent Phase II trial with
NT2N cells implanted into the peri-infarct or peri-hemorrhagic
cavity showed no increase in adverse events (Kondziolka
et al., 2005). An open-label, single-blinded randomized trial
using mesenchymal stem cells (MSCs) showed significant
improvement in functional outcome based on the modified Ran-
kin scale (a functional outcome scale with 0–3 being able to walk
with varying degrees of disability) in the treatment group without
a difference in adverse events, and multiple other trials have
shown safety and feasibility (Lee et al., 2010; Bhasin et al.,
2011, 2013). In addition, trials using bone marrow mononuclear
cells (BMMNCs) have shown safety and feasibility in the acute
and chronic phases of recovery (Friedrich et al., 2012; Savitz
et al., 2011; Moniche et al., 2012). A phase 1/2A study that trans-
planted human modified bone marrow-derived stromal cells
showed safety and feasibility of direct intracerebral transplanta-
tion 6 months to 5 years post-stroke, with improvement in
neurological outcomes (Steinberg et al., 2014). The first neural
stem cell trial for ischemic stroke (PISCES) has been completed
with results showing promise. In this open-label, dose-escala-
tion study, no adverse events have been observed among
the preliminary results in 11 patients with follow up between 9
to 24 months, and functional outcomes were improved after
transplantation (D. Kalladka et al., 2014, European Stroke
Conference).
Multiple questions have been raised about translating cell
therapy to clinical applications. Thus far, tumorgenecity of cell
therapies has not been shown to be problematic. Demonstration
of efficacy in randomized, double-blinded trials is needed, but
numerous clinical trials are underway (Table 2) to determine
whether cell-based therapy will become the next modality of
restorative stroke therapeutics.
Modulating Circuits to Increase Stroke Recovery
A shift in the excitatory-inhibitory balance in neural networks
across the brain occurs after ischemia. In the setting of a long-
term depression of inhibitory signals mediated by gamma-
aminobutyric acid (GABA) receptors in bilateral hemispheres,
cortical hyperexcitability peaks several weeks after stroke and
can persist for months (Buchkremer-Ratzmann et al., 1996;
Schiene et al., 1996). Sustained increase in glutamate transmis-
sion for 4-weeks post-stroke also contributes to greater excit-
atory signals (Centonze et al., 2007). Modulation of the tonic
inhibition regulated by GABA(A) receptors improves functional
recovery in animal models (Clarkson et al., 2010). The unaffected
hemisphere also can influence the excitatory state of the
damaged hemisphere altering recovery (Murase et al., 2004).
Further regulation and understanding of the excitatory-inhibitory
balance may prove critical when designing therapeutic ap-
proaches for stroke recovery.
Stimulation Techniques. Cortical stimulation is an exciting area
of research aimed at restoring this excitatory-inhibitory balanceNeuron 87, July 15, 2015 ª2015 Elsevier Inc. 303
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improve stroke recovery. It is another method targeting multiple
signaling pathways as electrical fields are applied across large
areas of neural tissue. Noninvasive methods (i.e., repetitive
transcranial magnetic stimulation [rTMS] and transcranial direct
current stimulation [tDCS]) and invasive methods (i.e., implant-
able epidural electrodes) exist. Initially, animal models showed
functional improvement after stimulation of motor areas and later
stimulation of connected but separate pathways have shown ef-
ficacy (Kleim et al., 2003; Machado et al., 2009). Utilizing the fact
that high-frequency rTMS increases cortical excitability and low-
frequency stimulation decreases excitability, ipsilateral or
contralateral stimulation has shown to increase functional
improvement of the affected extremity for intermediate periods
(Khedr et al., 2005; Kirton et al., 2008; Conforto et al., 2012).
The role of the contralesional hemisphere after stroke is an
area of continued interest and may have beneficial as well as
detrimental effects on stroke recovery. The contralesional
hemisphere likely can be recruited to improve recovery, but it
also imposes increased inhibition on the affected hemisphere
especially in the primary motor strip (Murase et al., 2004). This
suppressive effect may be beneficial at reducing complications
such as seizures, but may prevent plasticity and functional re-
covery. The majority of therapies aim to restore the excitatory
balance between the two hemispheres in order to improve re-
covery. Stimulation with tDCS has found similar outcomes with
improvement after stroke during therapies and for short dura-
tions after stimulation (Hummel et al., 2005). Recent Cochrane
reviews of rTMS and tDCS both conclude that further studies
are required to determine these techniques’ role in stroke recov-
ery (Hao et al., 2013; Elsner et al., 2013). Longer term efficacy is
currently being studied with randomized, double-blinded trials to
evaluate the utility of these treatment paradigms (Plow et al.,
2013).
Invasive cortical stimulation offers the advantage of stimulus
patterns of greater duration and at a more stable position. Given
that multiple sessions of non-invasive stimulation produce
longer sustained improvement, implantable electrodes provide
a unique method of delivering more continuous or frequent stim-
ulation (Khedr et al., 2005). Upper-extremity recovery is a signif-
icant limitation following stroke with only one-fifth of patients
obtaining full recovery at 6 months (Kwakkel et al., 2003). Animal
and pilot human studies have demonstrated improved recovery
and safety with invasive stimulation techniques (Kleim et al.,
2003; Levy et al., 2008). Based on these preliminary studies,
the Everest trial was initiated using cortical stimulation combined
with rehabilitation to improve upper-extremity recovery after
ischemia (Harvey et al., 2009). Unfortunately, this study was dis-
continued prematurely by the company (Northstar Neurosci-
ence). As we await the results of ongoing clinical trials, further
pre-clinical research is underway to help determine themost effi-
cacious locations and patterns for stimulation to improve stroke
recovery (Cheng et al., 2014). A better understanding of the
proper stimulation sites and paradigms should enable translation
of this technique to the clinical arena.
Optogenetics. With the growth in the field of optogenetics,
circuits in the brain can be more easily adjusted to tease apart
mechanisms of recovery. Because stimulation can be targeted304 Neuron 87, July 15, 2015 ª2015 Elsevier Inc.more precisely, the underlying circuits can be more carefully
evaluated. Using optogenetic technology, it was discovered
that even small ischemic injuries and depression in excitability
could lead to relatively large effects on motor circuits (Anen-
berg et al., 2014). In addition to contributing to our understand-
ing of the circuitry of the brain in the post-stroke environment,
optogenetics also has potential as a therapeutic modality.
Optogenetic techniques have been used to mitigate seizures
and similar strategies could be utilized to alter neural excit-
ability post-stroke (Paz et al., 2013). With the ability to stimulate
specific circuits, optogenetics serves as another useful tool
for stimulating defined neural pathways in particular brain re-
gions to improve recovery. A recent study demonstrated that
utilizing optogenetics to selectively stimulate ipsilesional pri-
mary motor cortex neurons after stroke improved functional
outcomes in a rodent model, as well as modulated neurotro-
phic factors in the contralesional cortex (Cheng et al., 2014).
A greater understanding of the exact regions that are critical
for recovery will allow stimulation to be more effectively tailored
to augment recovery. The requirement of gene alteration for
optogenetics currently limits it clinical applications, but as clin-
ical gene therapy advances, the use of optogenetics to modu-
late recovery pathways will be more easily translated to help
patients.
Altering Connections. With scientists focusing on the connec-
tome and the complicated neural circuits that integrate in the
brain to enable function, technologies that can alter these con-
nections may eventually offer therapeutic applications. One
such technology that is being investigated for multiple neurolog-
ical diseases, including essential tremor, is magnetic resonance-
guided focused ultrasound (MRgFUS) (Lipsman et al., 2014).
MRgFUS combines advanced MRI and ultrasound technology
to accurately focus ultrasonic energy to specific locations in
the brain. Several advances make this technology possible,
including (1) high-resolution brain and temperature mapping
with MRI, (2) merging of software and a phased array, ultrasound
transducer helmet to compensate for skull distortion, and (3)
technology enabling precise focusing of the ultrasonic energy.
MRgFUS allows for controlled thermal ablation of specific brain
regions (Clement and Hynynen, 2002). As our understanding of
the remodeling of circuits after ischemic injury (some beneficial
and some maladaptive) improves, we will be able to apply tech-
nology such as MRgFUS to enhance functional recovery. Addi-
tionally, MRgFUS has been show to disturb the blood-brain
barrier, which allows for therapeutic agents to more easily reach
an infarcted area (Hynynen et al., 2001). It may also be possible
to modulate circuits after stroke using stereotactic radiosurgery
techniques, including CyberKnife, Gamma Knife, linear acceler-
ator (LINAC) and cyclotron, which use focused radiation to place
tiny lesions in brain structures. These therapies have already
improved outcomes in select patients with Parkinson’s disease,
essential tremor, chronic pain, epilepsy, and mood disorders
(Romanelli et al., 2013; Kim and Lee, 2008; Lad et al., 2007;
Ohye et al., 2012). An innovative, non-invasive stimulation
method utilizing vibrotactile skin stimulation is currently being
planned for patients with epilepsy and may be applicable for
stroke patients as well (D’Alonzo and Cipriani, 2012). While these
technologies remain in their early stages with regards to clinical
Neuron
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different brain connections affect recovery and ultimately begin
to study their applications as stroke treatments.
Brain-Computer Interface. Given the elaborate networks con-
necting motor control regions of the brain to our muscles,
several methods of stroke recovery look to bypass damaged
areas of the brain and focus on healthy central or peripheral cir-
cuits. Because ischemia is usually an isolated event as opposed
to an ongoing neurodegenerative process, many of the neural
networks not affected by the infarct remain unharmed. Utilizing
technology to harness intact circuits in the brain has led to the
field of brain-computer interfaces. Through the study of extra-
cellular potentials, researchers have deciphered cortical repre-
sentation of motor movements (Moran and Schwartz, 1999).
Often movements are controlled by interpreting cortical activity
to induce movements in primates (Churchland et al., 2010), and
more recently, cortical signals recorded through high-density
microelectrode arrays or electrocorticography grids allowed
paralyzed patients the ability to control robotic limbs and com-
puter cursors (Hochberg et al., 2012; Collinger et al., 2013).
Alternative approaches stimulated pathways in the spinal cord
to induce movements for walking and hand function (Moritz
et al., 2007). Activation of spinal circuits has the benefit of trig-
gering multiple muscle groups required to perform a certain
task. Closed-loop systems have begun to explore the ability
for primates to control limb function by utilizing cortical
signals to stimulate spinal circuits to induce upper limb
movements (Zimmermann and Jackson, 2014). In patients
whose primary cortical areas have been damaged, alternative
areas must be trained, or remaining electromyography (EMG)
activity has also been used to trigger spinal cord circuits for
the performance of certain tasks (Amsuss et al., 2014; Zimmer-
mann and Jackson, 2014). Non-invasive methods such as
electroencephalography (EEG)-based systems have also been
implemented in neurorehabilitation programs, and as this tech-
nology is developed further, it may replace implantable arrays
(Ang et al., 2014). These methods are still limited by complica-
tions in long-term tissue/electronic interfaces and our ability to
accurately decipher integrated neural outputs of the cortex. As
our ability to interpret cortical signals and robotics continue
to advance, brain-computer interfaces offer exciting potential
to restore function to patients with hemiplegia or language
impairment from stroke.
Conclusions
Ischemic brain injury is a complicated disease affecting a variety
of brain regions, resulting in disruption of numerous neural
circuits and involving complex injury response. As we look to
the horizon for stroke recovery and therapeutics, a more holistic
approachmay be required. Utilizing treatments that altermultiple
cell injury pathways is likely needed to achieve clinically relevant
improvements. Currently, cell therapies and stimulation tech-
niques appear closest to clinical application, but many exciting
therapeutic approaches are being developed. Advances in
genomics, proteomics, and metabolomics will help to better
evaluate patients and their individual response to treatments.
A focus on modulating circuits that mediate recovery will
become increasingly important, and the burgeoning field ofbrain-computer interface has the potential to have a major
impact. As medicine becomes more personalized with a better
understanding of genetic implications on therapeutics, stroke
treatments will become more tailored to the individual patient
and specific stroke types. More sophisticated clinical outcome
scales to characterize patient deficits will allow for better evalu-
ation of treatments translated from the lab. As is most often the
case, new biomedical discoveries will continue to advance the
field and elucidate mechanisms of injury to guide novel thera-
peutics.
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